Exelixis | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 330.02M 27.49M 2025-06
Agios Pharmaceuticals USD 70.41M 18.04M 2025-06
Amgen USD 20.48B 2.53B 2025-06
AstraZeneca USD 33.54B 4.41B 2025-06
Bayer EUR 29.78B 1.82B 2025-06
BioMarin Pharmaceutical USD 684.25M 56.03M 2025-06
Bristol-Myers Squibb USD 27.53B 3.46B 2025-06
Cytokinetics USD 131.06M 28.66M 2025-06
Eisai JPY 411.61B 39.31B 2025-06
Eli Lilly USD 39.02B 8.95B 2025-06
Exelixis USD 336.11M 62.99M 2025-07
Genmab DKK 629M 127M 2025-06
Glaxosmithkline GBP 21.7B 238M 2024-12
Incyte USD 1.28B 608.18M 2025-06
Ionis Pharmaceuticals USD 897.24M 646.94M 2025-06
MacroGenics USD 55.53M 3.78M 2024-12
Merck USD 26.04B 863M 2025-06
Moderna USD 1.57B 32M 2025-06
Neurocrine Biosciences USD 546.3M 23.4M 2025-06
Novartis USD 31.71B 95M 2025-06
Pfizer USD 37.73B 1.27B 2025-06
Sanofi 29.16B 865M 2024-12
Takeda JPY 2.17T 336.94B 2025-06
Ultragenyx Pharmaceutical USD 293.24M 1.58M 2025-06
Xencor USD 96.08M 7.65M 2025-06


Exelixis Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.